Investigative antibody shows sustained efficacy in retinal disease studies

Results from Phase 3 trials of bispecific antibody faricimab demonstrate that it is more durable than currently available agents, and it has a good safety profile.

ASRS 39th Annual Scientific Meeting: A review of findings reported

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

Chronic non-infectious posterior uveitis: Dissecting real-world registry study of YUTIQ

Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

PDS with ranibizumab in nAMD offers similar results to ranibizumab monthly injections

October 11, 2021

Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.

Universal masking may lower risk of endophthalmitis after intravitreal anti-VEGF injections

October 10, 2021

During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.

The relationship between MIGS procedures and endophthalmitis

October 10, 2021

At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.